These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan. Kramers BJ; van Gastel MDA; Boertien WE; Meijer E; Gansevoort RT Am J Kidney Dis; 2019 Mar; 73(3):354-362. PubMed ID: 30578153 [TBL] [Abstract][Full Text] [Related]
23. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745 [TBL] [Abstract][Full Text] [Related]
24. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention. Côté G; Asselin-Thompstone L; Mac-Way F; René de Cotret P; Lacroix C; Desmeules S; Agharazii M Int Urol Nephrol; 2020 Feb; 52(2):343-349. PubMed ID: 32008201 [TBL] [Abstract][Full Text] [Related]
25. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Juul KV; Bichet DG; Nielsen S; Nørgaard JP Am J Physiol Renal Physiol; 2014 May; 306(9):F931-40. PubMed ID: 24598801 [TBL] [Abstract][Full Text] [Related]
26. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844 [TBL] [Abstract][Full Text] [Related]
27. Inner Ear Arginine Vasopressin-Vasopressin Receptor 2-Aquaporin 2 Signaling Pathway Is Involved in the Induction of Motion Sickness. Xu LH; Yang Y; Liu HX; Xiao SF; Qiu WX; Wang JX; Zhao CC; Gui YH; Liu GZ; Peng B; Li X; Wang GH; Zhou X; Jiang ZL J Pharmacol Exp Ther; 2020 May; 373(2):248-260. PubMed ID: 32165443 [TBL] [Abstract][Full Text] [Related]
28. Vasopressin actions in the kidney renin angiotensin system and its role in hypertension and renal disease. Gonzalez AA; Salinas-Parra N; Cifuentes-Araneda F; Reyes-Martinez C Vitam Horm; 2020; 113():217-238. PubMed ID: 32138949 [TBL] [Abstract][Full Text] [Related]
29. Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects. Al Therwani S; Mose FH; Jensen JM; Bech JN; Pedersen EB BMC Nephrol; 2014 Jun; 15():100. PubMed ID: 24965902 [TBL] [Abstract][Full Text] [Related]
30. Regulation of V2R transcription by hypertonicity and V1aR-V2R signal interaction. Izumi Y; Nakayama Y; Memetimin H; Inoue T; Kohda Y; Nonoguchi H; Tomita K Am J Physiol Renal Physiol; 2008 Oct; 295(4):F1170-6. PubMed ID: 18701631 [TBL] [Abstract][Full Text] [Related]
32. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574 [TBL] [Abstract][Full Text] [Related]
33. The effect of arginine vasopressin and its analogs on the synthesis of prostaglandin E2 by rat renal medullary interstitial cells in culture. Beck TR; Hassid A; Dunn MJ J Pharmacol Exp Ther; 1980 Oct; 215(1):15-9. PubMed ID: 7452479 [TBL] [Abstract][Full Text] [Related]